Paul Van Schil, MD, PhD, University Hospital Antwerp (UZA), Edegem, Belgium, discusses the evolution of surgery for lung cancer treatment with the wider introduction of adjuvant and neoadjuvant treatment. Although some clinicians suspect the use of surgery will decline, Prof. Schil believes this not to be the case, particularly for smaller lesions where the tumor can be analyzed for targetable mutations and does not need to be completely removed. This interview took place during the virtual European Lung Cancer Congress 2022.

свернуть